Morgan Stanley Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI) had its price target upped by Morgan Stanley from $40.00 to $42.00 in a research note published on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research analysts also recently issued reports on DNLI. B. Riley Financial upped their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Wall Street Zen raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Robert W. Baird set a $34.00 price objective on shares of Denali Therapeutics in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft upped their price target on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Finally, JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.15.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $20.96 on Wednesday. The company has a market cap of $3.35 billion, a P/E ratio of -12.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics has a one year low of $13.75 and a one year high of $27.30. The firm’s fifty day moving average price is $20.35 and its two-hundred day moving average price is $21.25.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.64. The business had revenue of $17.78 million during the quarter, compared to analyst estimates of $12.67 million. During the same quarter in the previous year, the firm posted ($0.74) earnings per share. Equities analysts expect that Denali Therapeutics will post -2.70 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,768 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the sale, the insider owned 278,995 shares in the company, valued at approximately $6,539,642.80. This trade represents a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Denali Therapeutics in the 2nd quarter worth about $360,759,000. Dimensional Fund Advisors LP lifted its stake in Denali Therapeutics by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock worth $51,687,000 after purchasing an additional 317,872 shares in the last quarter. ADAR1 Capital Management LLC raised its position in shares of Denali Therapeutics by 3,490.9% in the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after buying an additional 1,819,339 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Denali Therapeutics during the 2nd quarter valued at about $31,660,000. Finally, Defilade Capital Management L.P. lifted its position in Denali Therapeutics by 107.1% during the first quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company’s stock valued at $26,111,000 after purchasing an additional 703,256 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH sales and Q4 outlook: Net product revenue reached $17.8 million in the second full commercial quarter. Denali expects Q4 2026 product revenue of $30 million to $32 million, signaling substantial near-term growth. Denali Q3 2026 financial results and business highlights
• Positive Sentiment: Revenue beat estimates: Q3 revenue of $17.78 million topped analyst expectations of $12.67 million. The company also reported a $70.1 million net income for the quarter. Denali Therapeutics soars on earnings beat
• Positive Sentiment: Analyst targets raised: Morgan Stanley lifted its target to $42 and maintained Overweight; Wedbush raised its target to $24 and maintained Outperform. BTIG reaffirmed Buy with a $39 target. The higher targets reflect analyst optimism, though they are not guarantees of future performance. Read More., Read More., Read More.
• Positive Sentiment: Pipeline and balance sheet: Denali said a 2027 BLA filing for zafinofusp is on track and expects data from five TransportVehicle programs in 2027. Cash, equivalents and marketable securities totaled $1.0 billion. Denali Q3 2026 financial results and business highlights
• Neutral Sentiment: Earnings quality context: Q3 net income included a one-time $194 million gain from selling a Priority Review Voucher, so the reported profit is not solely reflective of recurring operations. Denali Q3 2026 financial results and business highlights

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.